76 results on '"Sue, Carolyn M."'
Search Results
2. Patient care standards for primary mitochondrial disease in Australia: an Australian adaptation of the Mitochondrial Medicine Society recommendations.
- Author
-
Sue, Carolyn M., Balasubramaniam, Shanti, Bratkovic, Drago, Bonifant, Catherine, Christodoulou, John, Coman, David, Crawley, Karen, Edema‐Hildebrand, Fabienne, Ellaway, Carolyn, Ghaoui, Roula, Kava, Maina, Kearns, Lisa S., Lee, Joy, Liang, Christina, Mackey, David A., Murray, Sean, Needham, Merrilee, Rius, Rocio, Russell, Jacqui, and Smith, Nicholas J.C.
- Subjects
- *
MEDICAL care standards , *MITOCHONDRIAL pathology , *PATIENTS , *MEDICAL protocols , *DISEASE prevalence , *CRITICAL care medicine , *OCCUPATIONAL adaptation , *DECISION making in clinical medicine , *DISEASE management , *MEDICAL logic - Abstract
This document provides consensus‐based recommendations for general physicians and primary care physicians who diagnose and manage patients with mitochondrial diseases (MD). It builds on previous international guidelines, with particular emphasis on clinical management in the Australian setting. This statement was prepared by a working group of medical practitioners, nurses and allied health professionals with clinical expertise and experience in managing Australian patients with MD. As new treatments and management plans emerge, these consensus‐based recommendations will continue to evolve, but current standards of care are summarised in this document. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
3. The pathogenesis of Parkinson's disease.
- Author
-
Morris, Huw R, Spillantini, Maria Grazia, Sue, Carolyn M, and Williams-Gray, Caroline H
- Subjects
- *
PARKINSON'S disease , *MITOCHONDRIAL pathology , *NEUROLOGICAL disorders , *DISABILITIES , *MOLECULAR pathology , *ALPHA-synuclein - Abstract
Parkinson's disease is a progressive neurodegenerative condition associated with the deposition of aggregated α-synuclein. Insights into the pathogenesis of Parkinson's disease have been derived from genetics and molecular pathology. Biochemical studies, investigation of transplanted neurons in patients with Parkinson's disease, and cell and animal model studies suggest that abnormal aggregation of α-synuclein and spreading of pathology between the gut, brainstem, and higher brain regions probably underlie the development and progression of Parkinson's disease. At a cellular level, abnormal mitochondrial, lysosomal, and endosomal function can be identified in both monogenic and sporadic Parkinson's disease, suggesting multiple potential treatment approaches. Recent work has also highlighted maladaptive immune and inflammatory responses, possibly triggered in the gut, that accelerate the pathogenesis of Parkinson's disease. Although there are currently no disease-modifying treatments for Parkinson's disease, we now have a solid basis for the development of rational neuroprotective therapies that we hope will halt the progression of this disabling neurological condition. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Patient-Derived Stem Cell Models in SPAST HSP: Disease Modelling and Drug Discovery.
- Author
-
Wali, Gautam, Sue, Carolyn M., and Mackay-Sim, Alan
- Subjects
- *
STEM cells , *NEURODEGENERATION - Abstract
Hereditary spastic paraplegia is an inherited, progressive paralysis of the lower limbs first described by Adolph Strümpell in 1883 with a further detailed description of the disease by Maurice Lorrain in 1888. Today, more than 100 years after the first case of HSP was described, we still do not know how mutations in HSP genes lead to degeneration of the corticospinal motor neurons. This review describes how patient-derived stem cells contribute to understanding the disease mechanism at the cellular level and use this for discovery of potential new therapeutics, focusing on SPAST mutations, the most common cause of HSP. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
5. Movement disorders in mitochondrial disease.
- Author
-
Ghaoui, Roula and Sue, Carolyn M.
- Subjects
- *
MITOCHONDRIAL pathology , *MOVEMENT disorders , *PARKINSONIAN disorders , *RESTLESS legs syndrome , *GENETIC mutation - Abstract
Mitochondrial disease presents with a wide spectrum of clinical manifestations that may appear at any age and cause multisystem dysfunction. A broad spectrum of movement disorders can manifest in mitochondrial diseases including ataxia, Parkinsonism, myoclonus, dystonia, choreoathetosis, spasticity, tremor, tic disorders and restless legs syndrome. There is marked heterogeneity of movement disorder phenotypes, even in patients with the same genetic mutation. Moreover, the advent of new technologies, such as next-generation sequencing, is likely to identify novel causative genes, expand the phenotype of known disease genes and improve the genetic diagnosis in these patients. Identification of the underlying genetic basis of the movement disorder is also a crucial step to allow for targeted therapies to be implemented as well as provide the basis for a better understanding of the molecular pathophysiology of the disease process. The aim of this review is to discuss the spectrum of movement disorders associated with mitochondrial disease. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Levodopa‐carbidopa intestinal gel: ‘dismantling the road blocks of a journey’.
- Author
-
Vijiaratnam, Nirosen and Sue, Carolyn M.
- Subjects
- *
DOPA , *DRUG therapy for Parkinson's disease , *METHYLDOPA , *PHARMACEUTICAL gels , *INTESTINES , *MEDICAL care costs , *ORAL drug administration , *QUALITY of life , *TREATMENT effectiveness , *THERAPEUTICS - Abstract
Abstract: Levodopa‐carbidopa intestinal gel offers superior treatment to standard oral therapy in selective patients with advanced Parkinson disease. The costs involved in instituting and maintaining this treatment are high but largely mitigated with the quality of life years the treatment offers. Key to this is ensuring a high retention rate once the treatment is instituted. We outline factors and considerations from our experience and viewpoints at each stage of the process to address in this ‘journey’ patients undertake that can help maximise retention rates and benefits. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Peripheral neuropathy in hereditary spastic paraplegia due to spastin (SPG4) mutation – A neurophysiological study using excitability techniques
- Author
-
Kumar, Kishore R., Sue, Carolyn M., Burke, David, and Ng, Karl
- Subjects
- *
PERIPHERAL neuropathy , *PARAPLEGIA , *NEUROPATHY , *SPASTICITY , *NEUROPHYSIOLOGY , *GENETIC mutation - Abstract
Abstract: Objective: To identify peripheral nerve abnormalities in hereditary spastic paraplegia (HSP) due to mutations in the spastin gene (spastic paraplegia 4, SPG4) using standard nerve conduction (NCS) and novel tests of axonal excitability. Methods: Eleven patients with known mutations in spastin were assessed with NCS for the upper and lower limbs, and axonal excitability testing on the median nerve. Results: Standard nerve conduction studies revealed a sensorimotor neuropathy in two patients. Excitability studies on median motor axons showed an isolated abnormality (increased strength-duration time constant), but those on sensory axons were normal in nine patients with normal routine nerve conduction studies. Conclusions: Peripheral neuropathy occurs in HSP patients with SPG4 mutations, but axonal excitability studies provide limited additional evidence for subclinical peripheral nerve dysfunction, and add little further to standard nerve conduction studies. Significance: The features of HSP due to SPG4 mutations include sensorimotor polyneuropathy. The value of excitability studies is limited in individual patients. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
8. The Association Between Olfactory Impairment and Total Mortality in Older Adults.
- Author
-
Gopinath, Bamini, Sue, Carolyn M., Kifley, Annette, and Mitchell, Paul
- Subjects
- *
STATISTICS on mortality of older people , *SMELL disorders , *COGNITION disorders , *HEALTH surveys ,MORTALITY risk factors - Abstract
Background. Population-based data on the relationship between impaired olfaction and risk of mortality among older adults are lacking. We used a representative cohort of adults aged 60 years or older to assess whether olfactory loss is a predictor of mortality, independent of potential confounders. Methods. Olfaction was measured by the San Diego Odor Identification Test (SDOIT) among 1,636 participants enrolled in the Blue Mountains Eye Study (2002–2004). Five-year all-cause mortality was confirmed using the Australian National Death Index. Results. More than one in five participants (21.8%) with olfactory impairment had died over the 5 years compared with less than 10% of participants without olfactory loss. Moderate olfactory loss (SDOIT score ≤3) was associated with a 68% increased risk of all-cause mortality (multivariable-adjusted hazard ratio, 1.68; 95% confidence interval, 1.10–2.56). This association did not persist after further adjustment for cognitive impairment. The association between olfactory loss and all-cause mortality was more marked among older participants (≥70 years) than younger participants (<70 years) with olfactory impairment (multivariable-adjusted hazard ratio, 1.48; 95% confidence interval, 1.02–2.15). However, adjusting for cognitive impairment diminished this association. Conclusions. Older adults with moderately impaired olfaction compared with those with normal olfaction had a higher risk of dying 5 years later. The relationship between olfaction and mortality, however, may be largely mediated by cognitive impairment in these older adults. Our findings highlight the value of identifying olfactory loss in the preclinical stage in the older patient before the development of related comorbidities. [ABSTRACT FROM PUBLISHER]
- Published
- 2012
- Full Text
- View/download PDF
9. The Genetics of Mitochondrial Disease.
- Author
-
Davis, Ryan L. and Sue, Carolyn M.
- Subjects
- *
MITOCHONDRIA , *DNA , *MITOCHONDRIAL DNA , *GENETICS , *GENOMICS - Abstract
The discovery that defects in mitochondria and mitochondrial DNA could cause human disease has led to the development of a rapidly expanding group of disorders known as mitochondrial disease. Mitochondrial disease is so named because of the common feature of impaired mitochondrial function. The main function of the mitochondrion is to produce energy for the cell in the form of ATP. ATP is generated by the respiratory chain, a series of complex proteins that are located in the mitochondrial membrane, and are encoded for by both the mitochondrial and nuclear genomes. Consequently, mitochondrial disease can be caused by mutations in either mitochondrial or nuclear DNA. Given the distribution of mitochondria throughout the body, the specific properties of mitochondrial DNA, and the mitochondrion's dependence on nuclear genes for its normal function, the clinical presentation of mitochondrial disease can be highly variable. Thus, familiarity with typical clinical presentations and knowledge of the genes that contribute to mitochondrial function will aid the clinician in the recognition, diagnosis, and management of patients with this group of diverse disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
10. Supplemental oxygen and muscle metabolism in mitochondrial myopathy patients.
- Author
-
Trenell, Michael I., Sue, Carolyn M., Thompson, Campbell H., and Kemp, Graham J.
- Subjects
- *
MUSCLE diseases , *MUSCLE metabolism , *MITOCHONDRIA , *MITOCHONDRIAL pathology , *OXYGEN - Abstract
Patients with mitochondrial myopathy (MM) have a reduced capacity to perform exercise due to a reduced oxidative capacity. We undertook this study to determine whether skeletal muscle metabolism could be improved with oxygen therapy in patients with MM. Six patients with MM and six controls, matched for age, gender and physical activity, underwent 31P-magnetic resonance spectroscopy (31P-MRS) examination. 31P-MR spectra were collected at rest and in series during exercise and recovery whilst breathing normoxic (0.21 O2) or hyperoxic (1.0 O2) air. At rest, MM showed an elevated [ADP] (18 ± 3 μmol/l) and pH (7.03 ± 0.01) in comparison to the control group (12 ± 1 μmol/l, 7.01 ± 0.01) ( P < 0.05) consistent with mitochondrial dysfunction. Oxygen supplementation did not change resting metabolites in either MM or the control group ( P > 0.05). Inferred maximal ATP synthesis rate improved by 33% with oxygen in MM (21 ± 3 vs. 28 ± 5 mmol/(l min), P < 0.05) but only improved by 5% in controls (40 ± 3 vs. 42 ± 3 mmol/(l min), P > 0.05). We conclude that oxygen therapy is associated with significant improvements in muscle metabolism in patients with MM. These data suggest that patients with MM could benefit from therapies which improve the provision of oxygen. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
11. Supplemental oxygen and muscle metabolism in mitochondrial myopathy patients.
- Author
-
Trenell, Michael I, Sue, Carolyn M, Thompson, Campbell H, and Kemp, Graham J
- Subjects
- *
ADENOSINE triphosphate metabolism , *MUSCLE disease treatment , *OXYGEN metabolism , *ADENOSINE diphosphate , *COMPARATIVE studies , *CONVALESCENCE , *EXERCISE , *HYDROGEN-ion concentration , *RESEARCH methodology , *MEDICAL cooperation , *MITOCHONDRIA , *MUSCLE contraction , *MUSCLE diseases , *NUCLEAR magnetic resonance spectroscopy , *OXYGEN therapy , *PHOSPHORUS , *RESEARCH , *RESEARCH funding , *EVALUATION research , *TREATMENT effectiveness , *SKELETAL muscle , *MITOCHONDRIAL myopathy , *THERAPEUTICS - Abstract
Patients with mitochondrial myopathy (MM) have a reduced capacity to perform exercise due to a reduced oxidative capacity. We undertook this study to determine whether skeletal muscle metabolism could be improved with oxygen therapy in patients with MM. Six patients with MM and six controls, matched for age, gender and physical activity, underwent (31)P-magnetic resonance spectroscopy ((31)P-MRS) examination. (31)P-MR spectra were collected at rest and in series during exercise and recovery whilst breathing normoxic (0.21 O(2)) or hyperoxic (1.0 O(2)) air. At rest, MM showed an elevated [ADP] (18 +/- 3 micromol/l) and pH (7.03 +/- 0.01) in comparison to the control group (12 +/- 1 micromol/l, 7.01 +/- 0.01) (P < 0.05) consistent with mitochondrial dysfunction. Oxygen supplementation did not change resting metabolites in either MM or the control group (P > 0.05). Inferred maximal ATP synthesis rate improved by 33% with oxygen in MM (21 +/- 3 vs. 28 +/- 5 mmol/(l min), P < 0.05) but only improved by 5% in controls (40 +/- 3 vs. 42 +/- 3 mmol/(l min), P > 0.05). We conclude that oxygen therapy is associated with significant improvements in muscle metabolism in patients with MM. These data suggest that patients with MM could benefit from therapies which improve the provision of oxygen. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
12. Mitochondrial DNA Deletion in a Child With Megaloblastic Anemia and Recurrent Encephalopathy.
- Author
-
Akman, Cigdem Inan, Sue, Carolyn M., Shanske, Sara, Tanji, Kurenai, Bonilla, Eduardo, Ojaimi, Joceline, Krishna, Sindu, Schubert, Romaine, and DiMauro, Salvatore
- Subjects
- *
MITOCHONDRIAL DNA , *BLOOD diseases , *MITOCHONDRIA , *SEPSIS , *TRANSFER RNA , *AMINO acids - Abstract
A 3½-year-old boy presented with megaloblastic anemia and recurrent episodes of severe lactic acidosis and coma. At age 4 years, he developed sepsis and died; postmortem examination failed to show any gross abnormality in any tissue. Biochemical analysis of muscle showed decreased activities for all respiratory chain enzymes except complex II. Muscle histochemistry revealed diffuse cytochrome c oxidase deficiency. Southern blot analysis of mitochondrial DNA from muscle, liver, and blood showed a heteroplasmic single mitochindrial DNA deletion of 2.4 kb, which removed the genes for cytochrome c oxidase I and II and the transfer ribonucleic acid genes for serine and aspartic acid. Single large-scale deletions in mitochondrial DNA have been associated with Pearson's syndrome, Kearns-Sayre syndrome, and progressive external ophthalmoplegia. This patient's presentation is unusual and suggests an overlap between Pearson's syndrome and Kearns-Sayre syndrome. (J Child Neurol 2004:19:258-261). [ABSTRACT FROM AUTHOR]
- Published
- 2004
- Full Text
- View/download PDF
13. Fatal infantile cardioencephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene.
- Author
-
Papadopoulou, Lefkothea C., Sue, Carolyn M., Davidson, Mercy M., Tanji, Kurenai, Nishino, Ichizo, Sadlock, James E., Krishna, Sindu, Walker, Winsome, Selby, Jeanette, Glerum, D. Moira, Coster, Rudy Van, Lyon, Gilles, Scalais, Emmanuel, Lebel, Roger, Kaplan, Paige, Shanske, Sara, De Vivo, Darryl C., Bonilla, Eduardo, and Hirano, Michio
- Subjects
- *
GENETIC mutation , *GENES , *CYTOCHROME oxidase - Abstract
Mammalian cytochrome c oxidase (COX) catalyses the transfer of reducing equivalents from cytochrome c to molecular oxygen and pumps protons across the inner mitochondrial membrane. Mitochondrial DNA (mtDNA) encodes three COX subunits (I?III) and nuclear DNA (nDNA) encodes ten. In addition, ancillary proteins are required for the correct assembly and function of COX (refs 2, 3, 4, 5, 6). Although pathogenic mutations in mtDNA-encoded COX subunits have been described, no mutations in the nDNA-encoded subunits have been uncovered in any mendelian-inherited COX deficiency disorder. In yeast, two related COX assembly genes, SCO1 and SCO2 (for synthesis of cytochrome c oxidase), enable subunits I and II to be incorporated into the holoprotein. Here we have identified mutations in the human homologue, SCO2, in three unrelated infants with a newly recognized fatal cardioencephalomyopathy and COX deficiency. Immunohistochemical studies implied that the enzymatic deficiency, which was most severe in cardiac and skeletal muscle, was due to the loss of mtDNA-encoded COX subunits. The clinical phenotype caused by mutations in human SCO2 differs from that caused by mutations in SURF1, the only other known COX assembly gene associated with a human disease, Leigh syndrome. [ABSTRACT FROM AUTHOR]
- Published
- 1999
- Full Text
- View/download PDF
14. The gut microbiota: A novel therapeutic target in Parkinson's disease?
- Author
-
Davis, Ryan L., Sue, Carolyn M., and Lubomski, Michal
- Subjects
- *
PARKINSON'S disease , *GUT microbiome , *CARBIDOPA , *RAPID eye movement sleep - Abstract
The gastrointestinal microbiota (GM) have become an increasingly topical area in the quest to better understand the pathogenesis of Parkinson's disease (PD). Studying the GM of PD patients, they showed that the enzyme tyrosine decarboxylase (TDC), predominately found within the GM, decarboxylates l-tyrosine to form tyramine and converts l-dopa to dopamine [[4]]. They did however identify a small molecule inhibitor, -fluoromethyltyrosine (AFMT), that prevented in vitro TDC-dependent l-dopa decarboxylation, as well as within Enterococcus faecalis cultures and GM samples from PD patients [[5]]. [Extracted from the article]
- Published
- 2019
- Full Text
- View/download PDF
15. How Do I Manage Patients With the Levodopa/Carbidopa Intestinal Gel?
- Author
-
Vijiaratnam, Nirosen and Sue, Carolyn M.
- Subjects
- *
PARKINSON'S disease , *DOPA , *CARBIDOPA , *COLLOIDS , *NEUROLOGICAL disorders - Abstract
The levodopa carbidopa intestinal gel is a device‐assisted therapy used for the management of fluctuating motor symptoms of Parkinson's disease that are refractory to oral therapy. The approach has demonstrable clinical value, but consideration of the associated need for expert care, access to services, and costs of the treatment impact the method of introduction to optimize uptake and minimize discontinuation across populations examined. Systematic approaches and modifications have been explored by different centers over the years to mitigate these considerations, with the aim of minimizing adverse events and maximizing the quality‐of‐life years gained with the treatment. In this presentation, we aim to outline an approach to managing this treatment while highlighting measures that can be utilized throughout the process to improve patients' experiences. View Supplementary Video 1 [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
16. Depression in Parkinson's disease: Perspectives from an Australian cohort.
- Author
-
Lubomski, Michal, Davis, Ryan L., and Sue, Carolyn M.
- Subjects
- *
PARKINSON'S disease , *IMPULSE control disorders , *RAPID eye movement sleep , *BEHAVIOR disorders , *BECK Depression Inventory , *SYMPTOMS , *DRUG therapy for Parkinson's disease , *RESEARCH , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *SEVERITY of illness index , *COMPARATIVE studies , *PSYCHOLOGICAL tests , *TRANSFERASES , *QUALITY of life , *MENTAL depression , *DISEASE complications - Abstract
Introduction: Depression is often an under-recognised feature of Parkinson's disease (PD). It is detrimental to physical and interpersonal functioning, negatively impacting a patient's clinical management, quality of life and well-being. We aimed to identify clinical predictors and management implications of depression in Australian PD patients.Methods: 103 PD and 81 Healthy Control (HC) subjects were evaluated using the Beck Depression Inventory (BDI) and other validated PD motor and non-motor symptom (NMS) tools.Results: Nearly twice as many PD patients were depressed, (38.9% vs 20.1%, p = 0.009), with a corresponding increase in depression severity on the BDI (11.9; standard deviation (SD) 8.8 vs 5.2; SD 5.5, p<0.001), and an odds ratio of 2.4 (95% confidence interval 1.2 - 4.7). Employment appeared to be a relative protective factor for depression, whilst patients requiring support services seemed to be more vulnerable to depression. Rapid Eye Movement Sleep Behaviour Disorder, dyskinesias, impulse control disorder, higher daily levodopa equivalent dose, increased motor severity, as well as catechol-O-methyltransferase inhibitor and amantadine use, all showed associations with depression (p<0.05). Chronic pain, decreased physical activity, constipation and upper gastrointestinal dysfunction presented with an apparent increase in risk for developing depression and increased depression severity. Other NMS were also found to be associated with PD-related depression.Limitations: Potential selection bias of self-reporting data collection from specialist PD clinics in a single metropolitan area.Conclusion: Our findings provide novel insight into the prevalence of depression in PD, possible contributory factors and future treatment strategies targeting depression in PD. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. Gastrointestinal dysfunction in Parkinson's disease.
- Author
-
Lubomski, Michal, Davis, Ryan L., and Sue, Carolyn M.
- Abstract
Background: Gastrointestinal (GI) dysfunction is prevalent in Parkinson's disease (PD). Symptoms are evident throughout the disease course, affect the length of the GI tract and impact on patient quality of life and management. We clarify real-life differences in the frequency and severity of GI symptoms in a cohort of PD and healthy control (HC) subjects. Methods: 103 PD patients were compared to 81 HC subjects. Outcome measures collected from validated questionnaires included constipation severity, upper and lower GI symptoms and physical activity. Results: PD patients were three-times more likely to experience constipation than HC subjects, (78.6% vs 28.4%), exhibited a fourfold increase in constipation severity and formed harder stools. PD patients also reported increased symptoms of indigestion, nausea, excessive fullness and bloating, compared to the HCs. A higher mean Leeds Dyspepsia Questionnaire score for PD patients (8.3 (standard deviation (SD) 7.7) vs 4.6 (SD 6.1), p = 0.001)) indicated increased symptom severity. Chronic pain was more frequently reported and correlated with constipation and upper GI dysfunction, being more prevalent and severe in women. Physical activity was notably decreased in the PD cohort (1823.6 (± 1693.6) vs 2942.4 (± 2620.9) metabolic equivalent-minutes/week, p = 0.001) and correlated with constipation severity. PD therapies were associated with increased fullness and bloating and harder stools. Conclusions: PD patients report more prevalent and severe GI dysfunction, although our cohort comprised of many later-stage participants. Earlier recognition of GI dysfunction in PD provides the opportunity to direct treatment for chronic pain and constipation, promote physical activity and rationalise PD therapies for optimal patient care. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. A Novel Homozygous Mutation in the FUCA1 Gene Highlighting Fucosidosis as a Cause of Dystonia: Case Report and Literature Review.
- Author
-
Wali, Gautam, Wali, G. M., Sue, Carolyn M., and Kumar, Kishore R.
- Subjects
- *
ANGIOKERATOMA corporis diffusum , *DYSTONIA , *BONE marrow transplantation , *LITERATURE reviews , *THIN layer chromatography - Abstract
Background Fucosidosis is a rare lysosomal disorder caused by mutations in the FUCA1 gene. We describe here a novel homozygous mutation in FUCA1 in an Indian fucosidosis case. Furthermore, we summarize the clinical and genetic findings in the most recently reported individuals with fucosidosis. Case The proband is an 8-year-old boy born to consanguineous parents. He had generalized dystonia and bilateral spasticity as well as coarse facies, dysostosis multiplex, recurrent infections, angiokeratoma corporis diffusum, and visceromegaly. Whole exome sequencing analysis detected a homozygous canonical splice variant in the FUCA1 gene [Chr1(GRCh37):g.24172346C > T; NM_000147.4:c.1261–1G > A], not previously reported as causative of a human phenotype. Low levels of α -fucosidase in patient leukocytes and a positive qualitative urine based thin layer chromatography test for fucosidosis confirmed the diagnosis. Our literature review identified 89 cases of fucosidosis since the last major review. We show that dystonia is a rare manifestation (12%) and that only a small minority of cases receive treatment with transplantation (3.37%). Conclusion We report a novel homozygous mutation in FUCA1 as the cause of severe neurological phenotype including generalized dystonia. Early recognition of fucosidosis may be important for consideration of promising treatment options, such as bone marrow transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. New insights into the complex role of mitochondria in Parkinson's disease.
- Author
-
Grünewald, Anne, Kumar, Kishore R., and Sue, Carolyn M.
- Subjects
- *
PARKINSON'S disease , *MITOCHONDRIAL DNA abnormalities , *MICRORNA , *CELLULAR immunity , *SUBSTANTIA nigra , *MITOCHONDRIAL DNA - Abstract
• Mitochondrial DNA abnormalities in the substantia nigra are associated with respiratory chain dysfunction. • There is a reciprocal interaction between alpha-synuclein aggregation and mitochondrial dysfunction. • There is strong evidence supporting a role for impaired mitophagy and mitochondrial biogenesis in Parkinson's disease. • Mitochondrial, mtDNA maintenance and lysosomal disease mechanisms may converge at the level of cell-mediated immunity. • Mitochondrial dysfunction is a target for novel drug therapies, although most clinical trials have failed to show benefit. New discoveries providing insights into mitochondrial bioenergetics, their dynamic interactions as well as their role in cellular homeostasis have dramatically advanced our understanding of the neurodegenerative process of Parkinson's disease (PD). Respiratory chain impairment is a key feature in sporadic PD patients and there is growing evidence that links proteins encoded by PD-associated genes to disturbances in mitochondrial function. Against the backdrop of latest advances in the development of PD treatments that target mitochondria, we aim to give an overview of the literature published in the last three decades on the significance of mitochondria in the pathogenesis of PD. We describe the contribution of mitochondrial genome alterations and PD-associated genes to mitochondrial maintenance. We highlight mitophagy as a key mechanism in neurodegeneration. Moreover, we focus on the reciprocal interaction between alpha-synuclein aggregation and mitochondrial dysfunction. We discuss a novel trafficking pathway involving mitochondrial-derived vesicles within the context of PD and provide a synopsis of the most recently emerging topics in PD research with respect to mitochondria. This includes the relationship between mitochondria and cell-mediated immunity, the ER-mitochondria axis, sirtuin-mediated mitochondrial stress response and the role of micro RNAs in the aetiology of PD. In addition, recent studies have challenged the neuro-centric view of PD pathology, moving microglia and astrocytes into the research spotlight. Greater insights into these mechanisms may hold the key for the development of novel targeted therapies, addressing the need for a disease-modifying treatment, which has remained elusive to date. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
20. Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review.
- Author
-
Siow, Sue-Faye, Yeow, Dennis, Rudaks, Laura I., Jia, Fangzhi, Wali, Gautam, Sue, Carolyn M., and Kumar, Kishore R.
- Subjects
- *
FAMILIAL spastic paraplegia , *DIFFUSION tensor imaging , *CLINICAL trials , *PATIENT reported outcome measures , *MAGNETIC resonance imaging - Abstract
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity. There is no disease-modifying treatment currently available. Therefore, standardized, validated outcome measures to facilitate clinical trials are urgently needed. We performed a scoping review of outcome measures and biomarkers for HSP to provide recommendations for future studies and identify areas for further research. We searched Embase, Medline, Scopus, Web of Science, and the Central Cochrane database. Seventy studies met the inclusion criteria, and eighty-three outcome measures were identified. The Spastic Paraplegia Rating Scale (SPRS) was the most widely used (27 studies), followed by the modified Ashworth Scale (18 studies) and magnetic resonance imaging (17 studies). Patient-reported outcome measures (PROMs) were infrequently used to assess treatment outcomes (28% of interventional studies). Diffusion tensor imaging, gait analysis and neurofilament light chain levels were the most promising biomarkers in terms of being able to differentiate patients from controls and correlate with clinical disease severity. Overall, we found variability and inconsistencies in use of outcome measures with a paucity of longitudinal data. We highlight the need for (1) a standardized set of core outcome measures, (2) validation of existing biomarkers, and (3) inclusion of PROMs in HSP clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
21. Genetic Testing in Parkinson's Disease.
- Author
-
Pal, Gian, Cook, Lola, Schulze, Jeanine, Verbrugge, Jennifer, Alcalay, Roy N., Merello, Marcelo, Sue, Carolyn M., Bardien, Soraya, Bonifati, Vincenzo, Chung, Sun Ju, Foroud, Tatiana, Gatto, Emilia, Hall, Anne, Hattori, Nobutaka, Lynch, Tim, Marder, Karen, Mascalzoni, Deborah, Novaković, Ivana, Thaler, Avner, and Raymond, Deborah
- Abstract
Genetic testing for persons with Parkinson's disease is becoming increasingly common. Significant gains have been made regarding genetic testing methods, and testing is becoming more readily available in clinical, research, and direct‐to‐consumer settings. Although the potential utility of clinical testing is expanding, there are currently no proven gene‐targeted therapies, but clinical trials are underway. Furthermore, genetic testing practices vary widely, as do knowledge and attitudes of relevant stakeholders. The specter of testing mandates financial, ethical, and physician engagement, and there is a need for guidelines to help navigate the myriad of challenges. However, to develop guidelines, gaps and controversies need to be clearly identified and analyzed. To this end, we first reviewed recent literature and subsequently identified gaps and controversies, some of which were partially addressed in the literature, but many of which are not well delineated or researched. Key gaps and controversies include: (1) Is genetic testing appropriate in symptomatic and asymptomatic individuals without medical actionability? (2) How, if at all, should testing vary based on ethnicity? (3) What are the long‐term outcomes of consumer‐ and research‐based genetic testing in presymptomatic PD? (4) What resources are needed for clinical genetic testing, and how is this impacted by models of care and cost‐benefit considerations? Addressing these issues will help facilitate the development of consensus and guidelines regarding the approach and access to genetic testing and counseling. This is also needed to guide a multidisciplinary approach that accounts for cultural, geographic, and socioeconomic factors in developing testing guidelines. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Healthcare resource utilization of patients with mitochondrial disease in an outpatient hospital setting.
- Author
-
Haque, Sameen, Crawley, Karen, Shrestha, Rupendra, Schofield, Deborah, and Sue, Carolyn M.
- Subjects
- *
MITOCHONDRIAL DNA , *MITOCHONDRIA , *NUCLEAR DNA , *MEDICAL care costs , *GENETIC disorder diagnosis - Abstract
Background and objectives: Mitochondrial diseases present as multi-system disorders requiring a comprehensive multidisciplinary approach. The data on healthcare resource utilization associated with mitochondrial diseases and the clinical drivers of these costs are limited including for the out-patient setting where the majority of the clinical care for mitochondrial disease patients occurs. We performed a cross-sectional retrospective study of out-patient healthcare resource utilization and costs for patients with a confirmed diagnosis of mitochondrial disease. Methods: We recruited participants from the Mitochondrial Disease Clinic in Sydney and stratified them into three groups: those with mitochondrial DNA (mtDNA) mutations (Group 1), those with nuclear DNA (nDNA) mutations and the predominant phenotype of chronic progressive external ophthalmoplegia (CPEO) or optic atrophy (Group 2) and those without a confirmed genetic diagnosis but clinical criteria and muscle biopsy findings supportive of a diagnosis of mitochondrial disease (Group 3). Data was collected through retrospective chart review and out-patient costs were calculated using the Medicare Benefits Schedule. Results: We analyzed the data from 91 participants and found that Group 1 had the greatest average out-patient costs per person per annum ($838.02; SD 809.72). Neurological investigations were the largest driver of outpatient healthcare costs in all groups (average costs per person per annum:—Group 1: $364.11; SD 340.93, Group 2: $247.83; SD 113.86 and Group 3: $239.57; SD 145.69) consistent with the high frequency (94.5%) of neurological symptoms. Gastroenterological and cardiac-related out-patient costs were also major contributors to out-patient healthcare resource utilization in Groups 1 and 3. In Group 2, ophthalmology was the second-most resource intensive specialty ($136.85; SD 173.35). The Group 3 had the greatest average healthcare resource utilization per person over the entire duration of out-patient clinic care ($5815.86; SD 3520.40) most likely due to the lack of a molecular diagnosis and a less customized management approach. Conclusion: The drivers of healthcare resource utilization are dependent on the phenotype–genotype characteristics. Neurological, cardiac, and gastroenterological costs were the top three drivers in the out-patient clinics unless the patient had nDNA mutations with predominant phenotype of CPEO and/or optic atrophy wherein ophthalmological-related costs were the second most resource intensive driver. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Low disease risk and penetrance in Leber hereditary optic neuropathy.
- Author
-
Watson, Eloise C., Davis, Ryan L., Ravishankar, Shyamsundar, Copty, Joseph, Kummerfeld, Sarah, and Sue, Carolyn M.
- Subjects
- *
NEUROPATHY , *DISEASE vectors , *HUMAN genetics , *NUCLEOTIDE sequencing , *VISION disorders - Abstract
The risk of Leber hereditary optic neuropathy (LHON) has largely been extrapolated from disease cohorts, which underestimate the population prevalence of pathogenic primary LHON variants as a result of incomplete disease penetrance. Understanding the true population prevalence of primary LHON variants, alongside the rate of clinical disease, provides a better understanding of disease risk and variant penetrance. We identified pathogenic primary LHON variants in whole-genome sequencing data of a well-characterized population-based control cohort and found that the prevalence is far greater than previously estimated, as it occurs in approximately 1 in 800 individuals. Accordingly, we were able to more accurately estimate population risk and disease penetrance in LHON variant carriers, validating our findings by using other large control datasets. These findings will inform accurate counseling in relation to the risk of vision loss in LHON variant carriers and disease manifestation in their family. This Matters Arising paper is in response to Lopez Sanchez et al. (2021), published in The American Journal of Human Genetics. See also the response by Mackey et al. (2022), published in this issue. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Outcome measures for hereditary spastic paraplegia clinical trials: Learnings from an Australian HSP center.
- Author
-
Siow, Sue Faye, Waters, Amy, Coward, Sharon, Wali, Gautam, Ng, Karl, Sue, Carolyn M., and Kumar, Kishore R.
- Subjects
- *
FAMILIAL spastic paraplegia , *CLINICAL trials , *QUALITY of life measurement - Abstract
• SARA is recommended to supplement SPRS given ataxia is a frequent complication of genotypes such as SPG7. • A disease-specific patient reported outcome measure is for sensitive measurement of quality of life. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
25. Beyond what the eye can see.
- Author
-
Ahmad, Kate E., Fraser, Clare L., Sue, Carolyn M., and Barton, Jason J.S.
- Subjects
- *
OPTIC nerve diseases , *NEUROPATHY , *MITOCHONDRIAL DNA , *BLINDNESS , *GENETIC mutation - Abstract
A 45-year-old woman presented with acute sequential optic neuropathy resulting in bilateral complete blindness. No significant visual recovery occurred. Past medical history was relevant for severe preeclampsia with resultant renal failure, diabetes mellitus, and sudden bilateral hearing loss when she was 38 years old. There was a family history of diabetes mellitus in her mother. Testing for common causes of bilateral optic neuropathy did not reveal a diagnosis for her illness. The maternal and personal history of diabetes and deafness prompted testing for mitochondrial disease. The 3 primary mitochondrial DNA mutations responsible for Leber hereditary optic neuropathy were absent, but the patient was subsequently found to have a disease causing mitochondrial DNA mutation, m.13513G>A. The case illustrates the importance of early testing for mitochondrial disease and demonstrates that Leber hereditary optic neuropathy–like presentations may be missed if testing is limited to the 3 primary mutations. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
26. An Update on the Hereditary Spastic Paraplegias: New Genes and New Disease Models.
- Author
-
Kumar, Kishore R., Blair, Nicholas F., and Sue, Carolyn M.
- Subjects
- *
LEG diseases , *PARAPLEGIA , *GENETIC disorders , *PARAPARESIS , *PROTEIN-protein interactions , *MOLECULAR diagnosis , *PLURIPOTENT stem cells - Abstract
Aims The hereditary spastic paraplegias ( HSPs) are a heterogeneous group of disorders characterized by spasticity in the lower limbs. We provide an overview of HSP with an emphasis on recent developments. Methods A PubMed search using the term 'hereditary spastic paraplegia' and 'hereditary spastic paraparesis' was conducted for a period from January 2012 to January 2015. We discuss and critique the major studies in the field over this 36-month period. Results A total of 346 publications were identified, of which 47 were selected for review. We provide an update of the common forms of HSP and include patient videos. We also discuss how next-generation sequencing (NGS) has led to the accelerated discovery of new HSP genes, including B4 GALNT1, DDHD1, C19orf12, GBA2, TECPR2, DDHD2, C12orf65, REEP2, and IBA57. Moreover, a single study alone identified 18 previously unknown putative HSP genes and created a model for the protein interactions of HSP, called the ' HSPome.' Many of the newly reported genes cause rare, complicated, autosomal recessive forms of HSP. NGS also has important clinical applications by facilitating the molecular diagnosis of HSP. Furthermore, common genetic forms of HSP have been studied using new disease models, such as neurons derived from induced pluripotent stem cells. These models have been used to elucidate important disease mechanisms and have served as platforms to screen for candidate drug compounds. Conclusion The field of HSP research has been progressing at a rapid pace. The challenge remains in translating these advances into new targeted disease therapies. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
27. The role of ATP13A2 in Parkinson's disease: Clinical phenotypes and molecular mechanisms.
- Author
-
Park, Jin‐Sung, Blair, Nicholas F., and Sue, Carolyn M.
- Abstract
The importance of ATP13A2 (PARK9) in Parkinson's disease (PD) has emerged with the discovery that mutations in this gene cause Kufor-Rakeb syndrome, an autosomal recessive, juvenile-onset form of parkinsonism associated with the additional clinical triad of spasticity, supranuclear gaze palsy, and dementia. Eleven independent kindreds with homozygous or compound heterozygous ATP13A2 mutations have been identified. These reports make it clear that the condition exhibits considerable clinical heterogeneity, with a spectrum of disease even among family members carrying the same mutation. The relevance of the protein in sporadic PD is demonstrated by the presence of single heterozygous ATP13A2 mutations in this group of patients and altered expression of the gene in the substantia nigra from patients with the disease. The involvement of ATP13A2 in Zn2+ homeostasis has recently been demonstrated, with the molecular consequences of this disturbance causing lysosomal impairment, α-synuclein accumulation, and mitochondrial dysfunction. These discoveries provide a new understanding of the role that ATP13A2 plays in the development of PD and identify a therapeutic target that may ameliorate α-synuclein accumulation and lysosomal and mitochondrial dysfunction in Parkinson's disease. © 2015 International Parkinson and Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
28. The broadening spectrum of mitochondrial disease: Shifts in the diagnostic paradigm.
- Author
-
Liang, Christina, Ahmad, Kate, and Sue, Carolyn M.
- Subjects
- *
MITOCHONDRIAL pathology , *HISTOLOGY , *GENETIC mutation , *MITOCHONDRIAL physiology , *FIBROBLAST growth factors , *BIOMARKERS , *DIAGNOSIS - Abstract
Abstract: Background: The diagnosis of mitochondrial disease requires a complex synthesis of clinical, biochemical, histological, and genetic investigations. An expanding number of mitochondrial diseases are being recognized, despite their phenotypic diversity, largely due to improvements in methods to detect mutations in affected individuals and the discovery of genes contributing to mitochondrial function. Improved understanding of the investigational pitfalls and the development of new laboratory methodologies that lead to a molecular diagnosis have necessitated the field to rapidly adopt changes to its diagnostic approach. Scope of review: We review the clinical, investigational and genetic challenges that have resulted in shifts to the way we define and diagnose mitochondrial disease. Incorporation of changes, including the use of fibroblast growth factor 21 (FGF-21) and next generation sequencing techniques, may allow affected patients access to earlier molecular diagnosis and management. Major conclusions: There have been important shifts in the diagnostic paradigm for mitochondrial disease. Diagnosis of mitochondrial disease is no longer reliant on muscle biopsy alone, but should include clinical assessment accompanied by the use of serological biomarkers and genetic analysis. Because affected patients will be defined on a molecular basis, oligosymptomatic mutation carriers should be included in the spectrum of mitochondrial disease. Use of new techniques such as the measurement of serum FGF-21 levels and next-generation-sequencing protocols should simplify the diagnosis of mitochondrial disease. General significance: Improvements in the diagnostic pathway for mitochondrial disease will result in earlier, cheaper and more accurate methods to identify patients with mitochondrial disease. This article is part of a Special Issue entitled Frontiers of Mitochondrial Research. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
29. The impact of device-assisted therapies on the gut microbiome in Parkinson's disease.
- Author
-
Lubomski, Michal, Xu, Xiangnan, Holmes, Andrew J., Yang, Jean Y. H., Sue, Carolyn M., and Davis, Ryan L.
- Subjects
- *
PARKINSON'S disease , *GUT microbiome , *DEEP brain stimulation , *SHIGELLOSIS , *ORAL medication , *GROUP psychotherapy - Abstract
Background: Microbiome feedbacks are proposed to influence Parkinson's disease (PD) pathophysiology. A number of studies have evaluated the impact of oral medication on the gut microbiome (GM) in PD. However, the influence of PD device-assisted therapies (DATs) on the GM remains to be investigated. Objectives: To profile acute gut microbial community alterations in response to PD DAT initiation. Methods: Clinical data and stool samples were collected from 21 PD patients initiating either deep brain stimulation (DBS) or levodopa–carbidopa intestinal gel (LCIG) and ten spousal healthy control (HC) subjects. 16S amplicon sequencing of stool DNA enabled comparison of temporal GM stability between groups and with clinical measures, including disease alterations relative to therapy initiation. Results: We assessed GM response to therapy in the PD group by comparing pre-therapy (− 2 and 0 weeks) with post-therapy initiation timepoints (+ 2 and + 4 weeks) and HCs at baseline (0 weeks). Altered GM compositions were noted between the PD and HC groups at various taxonomic levels, including specific differences for DBS (overrepresentation of Clostridium_XlVa, Bilophila, Parabacteroides, Pseudoflavonifractor and underrepresentation of Dorea) and LCIG therapy (overrepresentation of Pseudoflavonifractor, Escherichia/Shigella, and underrepresentation of Gemmiger). Beta diversity changes were also found over the 4 week post-treatment initiation period. Conclusions: We report on initial short-term GM changes in response to the initiation of PD DATs. Prior to the introduction of the DAT, a PD-associated GM was observed. Following initiation of DAT, several DAT-specific changes in GM composition were identified, suggesting DATs can influence the GM in PD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
30. Single cell morphology distinguishes genotype and drug effect in Hereditary Spastic Paraplegia.
- Author
-
Wali, Gautam, Berkovsky, Shlomo, Whiten, Daniel R., Mackay-Sim, Alan, and Sue, Carolyn M.
- Subjects
- *
CELL morphology , *GENOTYPES , *PHARMACODYNAMICS , *FAMILIAL spastic paraplegia , *NEURODEGENERATION - Abstract
A central need for neurodegenerative diseases is to find curative drugs for the many clinical subtypes, the causative gene for most cases being unknown. This requires the classification of disease cases at the genetic and cellular level, an understanding of disease aetiology in the subtypes and the development of phenotypic assays for high throughput screening of large compound libraries. Herein we describe a method that facilitates these requirements based on cell morphology that is being increasingly used as a readout defining cell state. In patient-derived fibroblasts we quantified 124 morphological features in 100,000 cells from 15 people with two genotypes (SPAST and SPG7) of Hereditary Spastic Paraplegia (HSP) and matched controls. Using machine learning analysis, we distinguished between each genotype and separated them from controls. Cell morphologies changed with treatment with noscapine, a tubulin-binding drug, in a genotype-dependent manner, revealing a novel effect on one of the genotypes (SPG7). These findings demonstrate a method for morphological profiling in fibroblasts, an accessible non-neural cell, to classify and distinguish between clinical subtypes of neurodegenerative diseases, for drug discovery, and potentially for biomarkers of disease severity and progression. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
31. Mitochondrial disease in adults: recent advances and future promise.
- Author
-
Ng, Yi Shiau, Bindoff, Laurence A, Gorman, Gráinne S, Klopstock, Thomas, Kornblum, Cornelia, Mancuso, Michelangelo, McFarland, Robert, Sue, Carolyn M, Suomalainen, Anu, Taylor, Robert W, Thorburn, David R, and Turnbull, Doug M
- Subjects
- *
MITOCHONDRIAL pathology , *ADULTS , *MITOCHONDRIA , *NUCLEOTIDE sequencing , *REPRODUCTIVE technology , *SMALL molecules - Abstract
Mitochondrial diseases are some of the most common inherited neurometabolic disorders, and major progress has been made in our understanding, diagnosis, and treatment of these conditions in the past 5 years. Development of national mitochondrial disease cohorts and international collaborations has changed our knowledge of the spectrum of clinical phenotypes and natural history of mitochondrial diseases. Advances in high-throughput sequencing technologies have altered the diagnostic algorithm for mitochondrial diseases by increasingly using a genetics-first approach, with more than 350 disease-causing genes identified to date. While the current management strategy for mitochondrial disease focuses on surveillance for multisystem involvement and effective symptomatic treatment, new endeavours are underway to find better treatments, including repurposing current drugs, use of novel small molecules, and gene therapies. Developments made in reproductive technology offer women the opportunity to prevent transmission of DNA-related mitochondrial disease to their children. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
32. Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance.
- Author
-
San Luciano, Marta, Tanner, Caroline M., Meng, Cheryl, Marras, Connie, Goldman, Samuel M., Lang, Anthony E., Tolosa, Eduardo, Schüle, Birgitt, Langston, J. William, Brice, Alexis, Corvol, Jean‐Christophe, Goldwurm, Stefano, Klein, Christine, Brockman, Simone, Berg, Daniela, Brockmann, Kathrin, Ferreira, Joachim J., Tazir, Meriem, Mellick, George D., and Sue, Carolyn M.
- Abstract
Background: The penetrance of leucine rich repeat kinase 2 (LRRK2) mutations is incomplete and may be influenced by environmental and/or other genetic factors. Nonsteroidal anti‐inflammatory drugs (NSAIDs) are known to reduce inflammation and may lower Parkinson's disease (PD) risk, but their role in LRRK2‐associated PD is unknown. Objectives: The objective of this study is to evaluate the association of regular NSAID use and LRRK2‐associated PD. Methods: Symptomatic ("LRRK2‐PD") and asymptomatic ("LRRK2‐non‐PD") participants with LRRK2 G2019S, R1441X, or I2020T variants (definitely pathogenic variant carriers) or G2385R or R1628P variants (risk variant carriers) from 2 international cohorts provided information on regular ibuprofen and/or aspirin use (≥2 pills/week for ≥6 months) prior to the index date (diagnosis date for PD, interview date for non‐PD). Multivariate logistic regression was used to evaluate the relationship between regular NSAID use and PD for any NSAID, separately for ibuprofen and aspirin in all carriers and separately in pathogenic and risk variant groups. Results: A total of 259 LRRK2‐PD and 318 LRRK2‐non‐PD participants were enrolled. Regular NSAID use was associated with reduced odds of PD in the overall cohort (odds ratio [OR], 0.34; 95% confidence interval [CI], 0.21–0.57) and in both pathogenic and risk variant carriers (ORPathogenic, 0.38; 95% CI, 0.21–0.67 and ORRiskVariant, 0.19; 95% CI, 0.04–0.99). Similar associations were observed for ibuprofen and aspirin separately (ORIbuprofen, 0.19; 95% CI, 0.07–0.50 and ORAspirin, 0.51; 95% CI, 0.28–0.91). Conclusions: Regular NSAID use may be associated with reduced penetrance in LRRK2‐associated PD. The LRRK2 protein is involved in inflammatory pathways and appears to be modulated by regular anti‐inflammatory use. Longitudinal observational and interventional studies of NSAID exposure and LRRK2‐PD are needed to confirm this association. © 2020 International Parkinson and Movement Disorder Society [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
33. Parkinson's disease and the gastrointestinal microbiome.
- Author
-
Lubomski, Michal, Tan, Ai Huey, Lim, Shen-Yang, Holmes, Andrew J., Davis, Ryan L., and Sue, Carolyn M.
- Subjects
- *
PARKINSON'S disease , *ENTERIC nervous system , *GASTROINTESTINAL diseases , *PATHOLOGY , *SYMPTOMS - Abstract
Recently, there has been a surge in awareness of the gastrointestinal microbiome (GM) and its role in health and disease. Of particular note is an association between the GM and Parkinson's disease (PD) and the realisation that the GM can act via a complex bidirectional communication between the gut and the brain. Compelling evidence suggests that a shift in GM composition may play an important role in the pathogenesis of PD by facilitating the characteristic ascending neurodegenerative spread of α-synuclein aggregates from the enteric nervous system to the brain. Here, we review evidence linking GM changes with PD, highlighting mechanisms supportive of pathological α-synuclein spread and intestinal inflammation in PD. We summarise existing patterns and correlations seen in clinical studies of the GM in PD, together with the impacts of non-motor symptoms, medications, lifestyle, diet and ageing on the GM. Roles of GM modulating therapies including probiotics and faecal microbiota transplantation are discussed. Encouragingly, alterations in the GM have repeatedly been observed in PD, supporting a biological link and highlighting it as a potential therapeutic target. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
34. Increased Diagnostic Yield of Spastic Paraplegia with or Without Cerebellar Ataxia Through Whole-Genome Sequencing.
- Author
-
Kim, Aryun, Kumar, Kishore R., Davis, Ryan L., Mallawaarachchi, Amali C., Gayevskiy, Velimir, Minoche, Andre E., Walls, Zachary, Kim, Han-Joon, Jang, Mihee, Cowley, Mark J., Choi, Ji-Hyun, Shin, Chaewon, Sue, Carolyn M., and Jeon, Beomseok
- Subjects
- *
CEREBELLAR ataxia , *FAMILIAL spastic paraplegia , *FRIEDREICH'S ataxia , *DNA copy number variations , *PARAPLEGIA , *ATAXIA - Abstract
Inherited disorders of spasticity or ataxia exist on a spectrum with overlapping causative genes and phenotypes. We investigated the use of whole-genome sequencing (WGS) to detect a genetic cause when considering this spectrum of disorders as a single group. We recruited 18 Korean individuals with spastic paraplegia with or without cerebellar ataxia in whom common causes of hereditary cerebellar ataxia and hereditary spastic paraplegia had been excluded. We performed WGS with analysis for single nucleotide variants, small insertions and deletions, copy number variants (CNVs), structural variants (SVs) and intronic variants. Disease-relevant variants were identified in ABCD1 (n = 3), CAPN1 (n = 2), NIPA1 (n = 1) and PLA2G6 (n = 1) for 7/18 patients (38.9%). A 'reverse phenotyping' approach was used to clarify the diagnosis in individuals with PLA2G6 and ABCD1 variants. One of the ABCD1 disease-relevant variants was detected on analysis for intronic variants. No CNV or SV causes were found. The two males with ABCD1 variants were initiated on monitoring for adrenal dysfunction. This is one of only a few studies to analyse spastic-ataxias as a continuous spectrum using a single approach. The outcome was improved diagnosis of unresolved cases for which common genetic causes had been excluded. This includes the detection of ABCD1 variants which had management implications. Therefore, WGS may be particularly relevant to diagnosing spastic ataxias given the large number of genes associated with this condition and the relatively high diagnostic yield. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
35. Genetic mimics of cerebral palsy.
- Author
-
Pearson, Toni S., Pons, Roser, Ghaoui, Roula, and Sue, Carolyn M.
- Abstract
The term "cerebral palsy mimic" is used to describe a number of neurogenetic disorders that may present with motor symptoms in early childhood, resulting in a misdiagnosis of cerebral palsy. Cerebral palsy describes a heterogeneous group of neurodevelopmental disorders characterized by onset in infancy or early childhood of motor symptoms (including hypotonia, spasticity, dystonia, and chorea), often accompanied by developmental delay. The primary etiology of a cerebral palsy syndrome should always be identified if possible. This is particularly important in the case of genetic or metabolic disorders that have specific disease-modifying treatment. In this article, we discuss clinical features that should alert the clinician to the possibility of a cerebral palsy mimic, provide a practical framework for selecting and interpreting neuroimaging, biochemical, and genetic investigations, and highlight selected conditions that may present with predominant spasticity, dystonia/chorea, and ataxia. Making a precise diagnosis of a genetic disorder has important implications for treatment, and for advising the family regarding prognosis and genetic counseling. © 2019 International Parkinson and Movement Disorder Society. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
36. High Degree of Genetic Heterogeneity for Hereditary Cerebellar Ataxias in Australia.
- Author
-
Kang, Ce, Liang, Christina, Ahmad, Kate E., Gu, Yufan, Siow, Sue-Faye, Colebatch, James G., Whyte, Scott, Ng, Karl, Cremer, Philip D., Corbett, Alastair J., Davis, Ryan L., Roscioli, Tony, Cowley, Mark J., Park, Jin-Sung, Sue, Carolyn M., and Kumar, Kishore R.
- Subjects
- *
GENETIC testing , *DISEASES , *AGE of onset - Abstract
Genetic testing strategies such as next-generation sequencing (NGS) panels and whole genome sequencing (WGS) can be applied to the hereditary cerebellar ataxias (HCAs), but their exact role in the diagnostic pathway is unclear. We aim to determine the yield from genetic testing strategies and the genetic and phenotypic spectrum of HCA in Australia by analysing real-world data. We performed a retrospective review on 87 HCA cases referred to the Neurogenetics Clinic at the Royal North Shore Hospital, Sydney, Australia. Probands underwent triplet repeat expansion testing; those that tested negative had NGS-targeted panels and WGS testing when available. In our sample, 58.6% were male (51/87), with an average age at onset of 37.1 years. Individuals with sequencing variants had a prolonged duration of illness compared to those with a triplet repeat expansion. The detection rate in probands for routine repeat expansion panels was 13.8% (11/80). NGS-targeted panels yielded a further 11 individuals (11/32, 34.4%), with WGS yielding 1 more diagnosis (1/3, 33.3%). NGS panels and WGS improved the overall diagnostic rate to 28.8% (23/80) in 14 known HCA loci. The genetic findings included novel variants in ANO10, CACNA1A, PRKCG and SPG7. Our findings highlight the genetic heterogeneity of HCAs and support the use of NGS approaches for individuals who were negative on repeat expansion testing. In comparison to repeat disorders, individuals with sequencing variants may have a prolonged duration of illness, consistent with slower progression of disease. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
37. Single Heterozygous ATP13A2 Mutations Cause Cellular Dysfunction Associated with Parkinson's Disease.
- Author
-
Park, Jin‐Sung, Koentjoro, Brianada, Klein, Christine, Sue, Carolyn M., and Park, Jin-Sung
- Subjects
- *
GENETIC mutation - Published
- 2018
- Full Text
- View/download PDF
38. Practical approaches to commencing device-assisted therapies for Parkinson disease in Australia.
- Author
-
Williams, David R., Evans, Andrew H., Fung, Victor S. C., Hayes, Michael, Iansek, Robert, Kimber, Thomas, O'Sullivan, John D., and Sue, Carolyn M.
- Subjects
- *
PARKINSON'S disease treatment , *DOPA , *APOMORPHINE , *MOVEMENT disorders , *QUALITY of life , *SURVEYS , *METHYLDOPA , *DEEP brain stimulation - Abstract
In Australia 1% of individuals aged over 50 years have Parkinson disease ( PD). Guidance for commencing device-assisted therapies ( DAT) for PD in Australia was developed based on a review of European recommendations and their relevance to the local clinical setting. An online survey and teleconference discussions were held by a group of eight local movement disorder experts to develop consensus. Referral to a movement disorder specialist and consideration of DAT is appropriate when motor fluctuations cause disability or reduced quality of life, response to treatment is inconsistent or motor fluctuations and dyskinesias require frequent treatment adjustment without apparent benefit and levodopa is required four or more times daily. Three types of DAT are available in Australia for patients with PD: continuous subcutaneous apomorphine; continuous levodopa-carbidopa intestinal gel infusion; and deep brain stimulation. All improve consistency of motor response. The most important aspects when considering which DAT to use are the preferences of the patient and their carers, patient comorbidities, age, cognitive function and neuropsychiatric status. Patients and their families need to be provided with treatment options that are suitable to them, with adequate explanations regarding the recommendations and comparison of potential device-related complications. DAT are best managed, where possible, in a specialist centre with experience in all three types of therapy. Proactive and early management of symptoms during disease progression is essential to maintain optimally motor responses and quality of life in patients with PD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
39. Parkin western blotting is useful for identification of patients with Parkin-related Parkinson's disease.
- Author
-
Koentjoro, Brianada, Park, Jin-Sung, and Sue, Carolyn M.
- Subjects
- *
PARKINSON'S disease diagnosis , *WESTERN immunoblotting , *GENETIC mutation , *FIBROBLASTS , *MISSENSE mutation - Abstract
The article offers information on diagnosis of patients with Parkinson's disease (PD) with use of western blotting technique to identify PD related genes. It states that western blotting was performed on fibroblast cells derived from PD patients having known genetic mutations. It concludes that western blotting is efficient in diagnosis of PD as it identifies PD protein expression but further mutational analysis should also be done to eradicate false positive results due to missense mutation.
- Published
- 2014
- Full Text
- View/download PDF
40. Nix restores mitophagy and mitochondrial function to protect against PINK1/Parkin-related Parkinson's disease.
- Author
-
Koentjoro, Brianada, Park, Jin-Sung, and Sue, Carolyn M.
- Abstract
Therapeutic targets are needed to develop neuroprotective treatments for Parkinson's disease (PD). Mitophagy, the selective autophagic elimination of dysfunctional mitochondria, is essential for the maintenance of mitochondrial integrity and is predominantly regulated by the PINK1/Parkin-mediated pathway. Loss of function mutations in Parkin and PINK1 cause an accumulation of dysfunctional mitochondria, leading to nigral neurodegeneration and early-onset PD with a high penetrance rate. We previously identified an asymptomatic homozygous Parkin mutation carrier who had not developed PD by her eighth decade despite the loss of functional Parkin. Here we discover a putative mechanism that protects her against PD. In contrast to Parkin-related PD patient-derived cells, the asymptomatic carrier cells show preserved mitochondrial function and mitophagy which is mediated by mitochondrial receptor Nip3-like protein X (Nix). Nix-mediated mitophagy was not affected by PINK1 knockdown. Both genetic and pharmacological induction of Nix restores mitophagy in PINK1- and Parkin-related PD patient cell lines, confirming its ability to induce mitophagy in the absence of PINK1/Parkin-mediated pathway. Moreover, Nix over-expression improves mitochondrial ATP production in these patient cells. Our results demonstrate that Nix can serve as an alternative mediator of mitophagy to maintain mitochondrial turnover, identifying Nix as a promising target for neuroprotective treatment in PINK1/Parkin-related PD. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
41. Neurophysiological Features Of Hemiballism.
- Author
-
Tai, Yi‐cheng, Yin, Yun Wo Katie, Ha, Ainhi D., Adam, Robert, Mahant, Neil, Sue, Carolyn M., and Fung, Victor S.C.
- Subjects
- *
MOVEMENT disorders , *NEUROLOGICAL disorders , *MUSCLES , *PATHOLOGICAL physiology , *MUSCULOSKELETAL system - Abstract
Hemiballism is a rare hyperkinetic movement disorder. The pathophysiology of hemiballism is poorly understood, and there have been few reports of neurophysiological recordings. The authors report three cases of hemiballism with associated radiological and neurophysiological findings. In patients 1 and 2, who were studied in the acute phase 4 and 14 days after presentation, irregularly timed and predominantly long-duration electromyographic ( EMG) bursts were observed typically ranging from 200 to 1500 milliseconds in duration and occurring asynchronously or alternating in antagonist muscles. In patient 3, who was studied 6 weeks after presentation when the involuntary movements had become choreiform, the EMG bursts were still from 200 to 1000 milliseconds in duration but were more synchronous or co-contracting. The flailing movements of hemiballism appear to occur as a result of prolonged bursts of EMG activity generated in individual muscles unopposed by EMG bursting in the antagonist. During the subacute phase when the movements become more choreiform, the results indicate that EMG activity becomes more synchronous or co-contracting. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
42. Reply letter to Jinnah "Locus pocus" and Albanese "Complex dystonia is not a category in the new 2013 consensus classification": Necessary evolution, no magic!
- Author
-
Klein, Christine, Lang, Anthony, van de Warrenburg, Bart P., Sue, Carolyn M., Tabrizi, Sarah J., Bertram, Lars, Mercimek ‐ Mahmutoglu, Saadet, Ebrahimi ‐ Fakhari, Darius, Warner, Thomas T., Durr, Alexandra, Assmann, Birgit, Kostic, Vladimir, Lohmann, Katja, and Marras, Connie
- Published
- 2016
- Full Text
- View/download PDF
43. Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons.
- Author
-
Mazzulli, Joseph R., Zunke, Friederike, Tsunemi, Taiji, Toker, Nicholas J., Jeon, Sohee, Burbulla, Lena F., Patnaik, Samarjit, Sidransky, Ellen, Marugan, Juan J., Sue, Carolyn M., and Krainc, Dimitri
- Subjects
- *
PARKINSON'S disease treatment , *PARKINSON'S disease & genetics , *SYNUCLEINS , *NEURAL physiology , *BETA-glucosidase , *MESENCEPHALON - Abstract
Parkinson's disease (PD) is characterized by the accumulation of a-synuclein (a-syn) within Lewy body inclusions in the nervous system. There are currently no disease-modifying therapies capable of reducing a-syn inclusions in PD. Recent data has indicated that loss-offunction mutations in the GBAl gene that encodes lysosomal β-gIucocerebrosidase (GCase) represent an important risk factor for PD, and can lead to α-syn accumulation. Here we use a small-molecule modulator of GCase to determine whether GCase activation within lysosomes can reduce α-syn levels and ameliorate downstream toxicity. Using induced pluripotent stem cell (iPSC)-derived human midbrain dopamine (DA) neurons from synucleinopathy patients with different PD-linked mutations, we find that a non-inhibitory small molecule modulator of GCase specifically enhanced activity within lysosomal compartments. This resulted in reduction of GCase substrates and clearance of pathological α-syn, regardless of the disease causing mutations. Importantly, the reduction of α-syn was sufficient to reverse downstream cellular pathologies induced by α-syn, including perturbations in hydrolase maturation and lysosomal dysfunction. These results indicate that enhancement of a single lysosomal hydrolase, GCase, can effectively reduce α-syn and provide therapeutic benefit in human midbrain neurons. This suggests that GCase activators may prove beneficial as treatments for PD and related synucleinopathies. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
44. Loss of ATP13A2 impairs glycolytic function in Kufor-Rakeb syndrome patient-derived cell models.
- Author
-
Park, Jin-Sung, Koentjoro, Brianada, Davis, Ryan L., and Sue, Carolyn M.
- Subjects
- *
GLYCOLS , *SYNDROMES , *AUTOSOMAL recessive polycystic kidney , *PARKINSON'S disease , *ENERGY metabolism - Abstract
Background: Kufor-Rakeb syndrome (KRS) is an autosomal recessive, juvenile-onset Parkinson's disease (PD) caused by loss-of-function mutations in ATP13A2 (PARK9). Impaired energy metabolism is considered a pathogenic mechanism in PD and mitochondrial dysfunction resulting from Zn(2+) dyshomeostasis has been found in KRS patient-derived cells. In addition to mitochondrial energy production, glycolysis plays an important role in cellular energy metabolism and glucose hypometabolism has been reported in PD. However, glycolytic status in KRS remains undetermined despite its potential importance.Methods: We assessed glycolytic function in ATP13A2-deficient KRS patient-derived human olfactory neurosphere cells and fibroblasts and determined the effect of pyruvate supplementation on improving cellular energy production.Results: We found impaired extracellular acidification, reduction in pyruvate production and a decrease in the NAD(+)/NADH ratio, indicative of glycolytic dysfunction. In addition, gene expression analysis revealed an altered expression profile for several glycolytic enzymes. Glycolytic dysfunction was aggravated when the intracellular Zn(2+) concentration was increased, while ATP13A2 overexpression and pyruvate supplementation blocked the observed Zn(2+)-mediated toxicity. Moreover, supplementation with pyruvate significantly increased basal mitochondrial ATP production and abolished Zn(2+)-induced cell death.Conclusions: These findings indicate that glycolytic dysfunction contributes to pathogenesis and pyruvate supplementation improves overall cellular bioenergetics in our KRS patient-derived cell model, highlighting a therapeutic potential. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
45. Nomenclature of genetic movement disorders: Recommendations of the international Parkinson and movement disorder society task force.
- Author
-
Marras, Connie, Lang, Anthony, van de Warrenburg, Bart P., Sue, Carolyn M., Tabrizi, Sarah J., Bertram, Lars, Mercimek‐Mahmutoglu, Saadet, Ebrahimi‐Fakhari, Darius, Warner, Thomas T., Durr, Alexandra, Assmann, Birgit, Lohmann, Katja, Kostic, Vladimir, Klein, Christine, Mercimek-Mahmutoglu, Saadet, and Ebrahimi-Fakhari, Darius
- Abstract
The system of assigning locus symbols to specify chromosomal regions that are associated with a familial disorder has a number of problems when used as a reference list of genetically determined disorders,including (I) erroneously assigned loci, (II) duplicated loci, (III) missing symbols or loci, (IV) unconfirmed loci and genes, (V) a combination of causative genes and risk factor genes in the same list, and (VI) discordance between phenotype and list assignment. In this article, we report on the recommendations of the International Parkinson and Movement Disorder Society Task Force for Nomenclature of Genetic Movement Disorders and present a system for naming genetically determined movement disorders that addresses these problems. We demonstrate how the system would be applied to currently known genetically determined parkinsonism, dystonia, dominantly inherited ataxia, spastic paraparesis, chorea, paroxysmal movement disorders, neurodegeneration with brain iron accumulation, and primary familial brain calcifications. This system provides a resource for clinicians and researchers that, unlike the previous system, can be considered an accurate and criterion-based list of confirmed genetically determined movement disorders at the time it was last updated. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
46. Functional hyperspectral imaging captures subtle details of cell metabolism in olfactory neurosphere cells, disease-specific models of neurodegenerative disorders.
- Author
-
Gosnell, Martin E., Anwer, Ayad G., Cassano, Juan C., Sue, Carolyn M., and Goldys, Ewa M.
- Subjects
- *
CELL metabolism , *NEURODEGENERATION , *HYPERSPECTRAL imaging systems , *BIOFLUORESCENCE , *ACIDOSIS , *DIAGNOSIS , *PATIENTS - Abstract
Hyperspectral imaging uses spectral and spatial image information for target detection and classification. In this work hyperspectral autofluorescence imaging was applied to patient olfactory neurosphere-derived cells, a cell model of a human metabolic disease MELAS (mitochondrial myopathy, encephalomyopathy, lactic acidosis, stroke-like syndrome). By using an endogenous source of contrast subtle metabolic variations have been detected between living cells in their full morphological context which made it possible to distinguish healthy from diseased cells before and after therapy. Cellular maps of native fluorophores, flavins, bound and free NADH and retinoids unveiled subtle metabolic signatures and helped uncover significant cell subpopulations, in particular a subpopulation with compromised mitochondrial function. Taken together, our results demonstrate that multispectral spectral imaging provides a new non-invasive method to investigate neurodegenerative and other disease models, and it paves the way for novel cellular characterisation in health, disease and during treatment, with proper account of intrinsic cellular heterogeneity. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
47. Expanding the phenotype of GMPPB mutations.
- Author
-
Cabrera-Serrano, Macarena, Ghaoui, Roula, Ravenscroft, Gianina, Johnsen, Russell D., Davis, Mark R., Corbett, Alastair, Reddel, Stephen, Sue, Carolyn M., Christina Liang, Waddell, Leigh B., Kaur, Simranpreet, Lek, Monkol, North, Kathryn N., MacArthur, Daniel G., Lamont, Phillipa J., Clarke, Nigel F., and Laing, Nigel G.
- Subjects
- *
MUSCULAR dystrophy , *GUANYLIC acid , *PHENOTYPES , *GENETIC mutation , *RHABDOMYOLYSIS - Abstract
Dystroglycanopathies are a heterogeneous group of diseases with a broad phenotypic spectrum ranging from severe disorders with congenital muscle weakness, eye and brain structural abnormalities and intellectual delay to adult-onset limb-girdle muscular dystrophies without mental retardation. Most frequently the disease onset is congenital or during childhood. The exception is FKRP mutations, in which adult onset is a common presentation. Here we report eight patients from five non-consanguineous families where next generation sequencing identified mutations in the GMPPB gene. Six patients presented as an adult or adolescent- onset limb-girdle muscular dystrophy, one presented with isolated episodes of rhabdomyolysis, and one as a congenital muscular dystrophy. This report expands the phenotypic spectrum of GMPPB mutations to include limb-girdle muscular dystrophies with adult onset with or without intellectual disability, or isolated rhabdomyolysis. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
48. Systematic review of cardiac electrical disease in Kearns-Sayre syndrome and mitochondrial cytopathy.
- Author
-
Kabunga, Peter, Lau, Antony K., Phan, Kevin, Puranik, Rajesh, Liang, Christina, Davis, Ryan L., Sue, Carolyn M., and Sy, Raymond W.
- Subjects
- *
KEARNS-Sayre syndrome , *SYSTEMATIC reviews , *MITOCHONDRIAL pathology , *CELLULAR pathology , *EYE paralysis , *RHODOPSIN , *HEART conduction system - Abstract
Kearns-Sayre syndrome (KSS) is a mitochondrial disorder characterised by onset before the age of 20 years, progressive external ophthalmoplegia, and pigmentary retinopathy, accompanied by either cardiac conduction defects, elevated cerebrospinal fluid protein or cerebellar ataxia. 50% of patients with KSS develop cardiac complications. The most common cardiac manifestation is conduction disease which may progress to complete atrioventricular block or bradycardia-related polymorphic ventricular tachycardia (PMVT). The management of cardiac electrical disease associated with KSS and mitochondrial cytopathy is systematically reviewed including the case of a 23 year-old female patient with KSS who developed a constellation of cardiac arrhythmias including rapidly progressive conduction system disease and monomorphic ventricular tachycardia with myocardial scarring. The emerging role of cardiac magnetic resonance imaging (CMR) in detecting subclinical cardiac involvement is also highlighted. This review illustrates the need for cardiologists to be informed about this rare but emerging condition. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
49. Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1.
- Author
-
Tomlinson, Susan Elizabeth, Rajakulendran, Sanjeev, Tan, Stella Veronica, Graves, Tracey Dawn, Bamiou, Doris-Eva, Labrum, Robyn W., Burke, David, Sue, Carolyn M., Giunti, Paola, Schorge, Stephanie, Kullmann, Dimitri M., and Hanna, Michael G.
- Subjects
- *
GENETIC mutation , *CEREBELLAR ataxia , *RESEARCH methodology , *IMMUNOCYTOCHEMISTRY , *ELECTROPHYSIOLOGY , *HEARING disorders - Abstract
Background and objective Heterozygous mutations in KCNA1 cause episodic ataxia type 1 (EA1), an ion channel disorder characterised by brief paroxysms of cerebellar dysfunction and persistent neuromyotonia. This paper describes four previously unreported families with EA1, with the aim of understanding the phenotypic spectrum associated with different mutations. Methods 15 affected individuals from four families underwent clinical, genetic and neurophysiological evaluation. The functional impact of new mutations identified in the KCNA1 gene was investigated with in vitro electrophysiology and immunocytochemistry. Results Detailed clinical documentation, dating back to 1928 in one family, indicates that all patients manifested episodic ataxia of varying severity. Four subjects from three families reported hearing impairment, which has not previously been reported in association with EA1. New mutations (R167M, C185W and I407M) were identified in three out of the four families. When expressed in human embryonic kidney cells, all three new mutations resulted in a loss of Kv1.1 channel function. The fourth family harboured a previously reported A242P mutation, which has not been previously described in association with ataxia. Conclusions The genetic basis of EA1 in four families is established and this report presents the earliest documented case from 1928. All three new mutations caused a loss of Kv1.1 channel function. The finding of deafness in four individuals raises the possibility of a link between Kv1.1 dysfunction and hearing impairment. Our findings broaden the phenotypic range associated with mutations in KCNA1. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
50. Long‐Term Follow‐Up and Evolution of ADCY5—From a Ballistic to Dystonic Phenotype.
- Author
-
Wali, Gurusidheshwar M., Wali, Gautam, Kumar, Kishore R., and Sue, Carolyn M.
- Subjects
- *
LONG-Term Evolution (Telecommunications) , *PHENOTYPES - Abstract
View Supplementary Video 1 View Supplementary Video 2 [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.